Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.

ABSTRACT:

Background

The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2).

Methods

We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review.

Results

Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned

SUBMITTER: Litton JK 

PROVIDER: S-EPMC10600918 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature